menu
    • menu
    [{"orgOrder":0,"company":"Nemysis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nemysis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nemysis \/ Not Applicable"},{"orgOrder":0,"company":"Nemysis","sponsor":"Bruno Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nemysis \/ Bruno Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Nemysis \/ Bruno Farmaceutici"},{"orgOrder":0,"company":"Nemysis","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Endoprotease 40 Glutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Nemysis \/ European Union","highestDevelopmentStatusID":"6","companyTruncated":"Nemysis \/ European Union"},{"orgOrder":0,"company":"Nemysis","sponsor":"Kolinpharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nemysis \/ Nemysis","highestDevelopmentStatusID":"12","companyTruncated":"Nemysis \/ Nemysis"}]

    Find Clinical Drug Pipeline Developments & Deals by Nemysis

    Menu

    Nemysis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nemysis

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Nemysis

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Hydroxide Adipate Tartrate

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Recipient : Kolinpharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nemysis Limited Signs with Kolinpharma SpA an IHAT Sales and Marketing Agreement

                            Details : Kolinpharma will market Iron Hydroxide Adipate Tartrate (IHAT), an oral iron supplement for iron deficiency, utilizing its existing sales network under the brand KIPFeR.

                            Brand Name : KIPFeR

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 10, 2024

                            Lead Product(s) : Iron Hydroxide Adipate Tartrate

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Recipient : Kolinpharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nemysis

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Nemysis

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endoprotease 40 Glutenase

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : European Union

                            Deal Size : $2.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Nemysis Limited Receives EU Horizon Grant Funding for E40

                            Details : The net proceeds will fund the completion of research & development to Market Authorization of Nemysis' novel E40 (endoprotease 40 glutenase) for the prevention of symptomatic gluten exposure in gluten intolerance and sensitivity.

                            Brand Name : E40

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 07, 2023

                            Lead Product(s) : Endoprotease 40 Glutenase

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : European Union

                            Deal Size : $2.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nemysis

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Nemysis

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Hydroxide Adipate Tartrate

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Bruno Farmaceutici

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nemysis Limited Signs IHAT Sales and Marketing Agreement

                            Details : Under the agreement, Bruno will use its existing sales network and relationships with relevant clinical communities to market IHAT (iron hydroxide adipate tartrate), an oral iron supplementation product, under its own brand.

                            Brand Name : IHAT

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 05, 2023

                            Lead Product(s) : Iron Hydroxide Adipate Tartrate

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Bruno Farmaceutici

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nemysis

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Nemysis

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Hydroxide Adipate Tartrate

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Chinese Patent for IHAT, the Novel Iron Nanoparticulate Supplement for Iron Deficiency (ID) and Iron Def...

                            Details : The patent claims describe methods for producing IHAT (Iron Hydroxide Adipate Tartrate), where Generally Recognised As Safe (GRAS) organic acids, and particularly Tartaric and Adipic acids, are used to modify the ferrihydrite nanocore of ferritin.

                            Brand Name : IHAT-02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 12, 2021

                            Lead Product(s) : Iron Hydroxide Adipate Tartrate

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth